ResearcherUniversity of Bari Aldo MoroActive in the last 2 years
Carmen Abate
Matched on ORCID iD 0000-0001-9292-884X; OpenAlex author ID A5064167499. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 6
- Correction to "First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer". Last author DOI 10.1021/acs.jmedchem.6c00085↗
- First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer. Last author DOI 10.1021/acs.jmedchem.4c01410↗
- New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4. Co-author DOI 10.3390/molecules27051682↗
- Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models. Last author DOI 10.1007/s13402-021-00638-5↗
- Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochond… Co-author DOI 10.1186/s12885-016-3040-4↗
- Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. Co-author DOI 10.1186/1756-9966-31-41↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mauro Niso · 5 shared papers, 2017–2026 · strength 0.84
- Paper Correction to "First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative S… DOI 10.1021/acs.jmedchem.6c00085↗
- Paper First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against… DOI 10.1021/acs.jmedchem.4c01410↗
- Paper Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic c… DOI 10.1007/s13402-021-00638-5↗
- Alessandra Barbanente · 2 shared papers, 2024–2026 · strength 0.45
- Paper Correction to "First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative S… DOI 10.1021/acs.jmedchem.6c00085↗
- Paper First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma-2 Receptor (S2R) as an Innovative Strategy against… DOI 10.1021/acs.jmedchem.4c01410↗
- Dario P. Anobile · 1 shared paper, 2022 · strength 0.16
- Amir Avan · 1 shared paper, 2022 · strength 0.16
- Elisa Giovannetti · 1 shared paper, 2022 · strength 0.16
- Dirk M. Spitzer · 2 shared papers, 2012–2017 · strength 0.11
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic canc… DOI 10.1186/1756-9966-31-41↗
- William G. Hawkins · 2 shared papers, 2012–2017 · strength 0.11
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic canc… DOI 10.1186/1756-9966-31-41↗
- John R. Hornick · 2 shared papers, 2012–2017 · strength 0.11
- Paper Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazin… DOI 10.1186/s12885-016-3040-4↗
- Paper Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic canc… DOI 10.1186/1756-9966-31-41↗
- Maria Laura Pati · 1 shared paper, 2017 · strength 0.08
- Peter S. Goedegebuure · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.